Protocol #APD811-303: A Study Evaluating the Long-Term Efficacy and Safety of RalinEpag in Subjects with PAH via an Open-Label EXTENSION
02/06/2019 - 02/06/2022 (PI)United Therapeutics Corporation
Protocol # STERIO-SCD, A Phase lib Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Assess the Safety, Tolerability, and Efficacy of Riociguat in Patients with Sickle Cell Diseases
03/20/2018 - 09/19/2021 (Subcontract PI)University of Pittsburgh Bayer HealthCare
Assessing the effectiveness of anti-sickling agents for sickle hemoglobin and red blood cells
02/01/2016 - 01/31/2021 (PI)General Hospital Corp d/b/a Massachusetts General Hospital
A Randomized, Double-blind, Parallel-group, Placebo-controlled Phase 2 Trial of APD811, an Oral IP Receptor Agonist, in Patients with Pulmonary Arterial Hypertension
12/12/2014 - 12/31/2020 (PI)Arena Pharmaceuticals Inc.
A StuDy eVAluatiNg the EfficaCy and Safety of RalinEpag To Improve Treatment OUTCOMES in PAH Patients
11/30/2018 - 11/30/2020 (PI)United Therapeutics Corporation
Hematopoietic Stem Cell Transplantation for Young Adults with Sickle Cell Disease
09/01/2015 - 07/31/2020 (Subcontract PI)Emory University NIH NHLBI5U01HL128566-03
Protocol # 402-C-1602, An Extended Access Program to Assess Long-Term Safety of Bardoxolone Methyl in Patients with Pulmonary Hypertension.
07/27/2017 - 07/26/2020 (PI)Reata Pharmaceuticals, Inc.
The efficacy and safety of initial triple versus initial dual oral combination therapy in patients with newly diagnosed pulmonary arterial hypertension: A multi-center, double-blind, placebo
07/15/2015 - 07/14/2020 (PI)Actelion Pharmaceuticals, Ltd.
Protocol # AC-055-512 RETRO: A Retrospective, multicEnter charT Review to collect dOsing information of PAH background medication in subject who participated in the AC-055-302 (SERAPHIN) double-blind
07/26/2018 - 05/31/2020 (PI)Actelion Pharmaceuticals, Ltd.
A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients with Pulmonary Arterial Hypertension
05/30/2014 - 05/31/2020 (PI)Reata Pharmaceuticals, Inc.
Showing 10 of 30 results.
Show All Results